IX 01

Drug Profile

IX 01

Alternative Names: IX-01

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Chorus Group; Ixchelsis
  • Class
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Premature ejaculation

Most Recent Events

  • 05 Dec 2016 Ixchelsis plans a phase IIb trial for Premature ejaculation
  • 01 Dec 2016 Ixchelsis Limited completes a phase I trial in Premature ejaculation (In volunteers) in USA (PO, Tablet and Liquid) (NCT02962531)
  • 01 Nov 2016 Phase-I clinical trials in Premature ejaculation (In volunteers) in USA (PO, Liquid) (NCT02962531)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top